Navigation Links
ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
Date:7/28/2014

MUNICH, July 28, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales of infringing headgear used on APEX WiZARD 210 and 220 masks.  The judgment was entered by the Regional District Court in Munich, is appealable, and applies throughout Germany. 

The permanent injunction continues a preliminary injunction that was entered by the same court on Nov. 12, 2013.  The court rejected APEX's request to stay the injunction and its challenge to the validity of ResMed's patent.  The judgment also requires APEX to forfeit its inventory of infringing products, to report on its sales of the infringing products, and to pay damages to ResMed.ResMed has also filed separate patent infringement lawsuits in the same court seeking damages and permanent injunctions to stop infringement of other ResMed patents. The trials of those cases will occur in the fall of 2014.  The additional accused products are:

  • The APEX iCH and XT Fit CPAP devices
  • The APEX WiZARD 210 and WiZARD 220 masks
  • "ResMed has a global business built on its investment in research and developments, resulting in products sold worldwide that excel in performance, quality and comfort," said David Pendarvis, ResMed global general counsel and chief administrative officer. "We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists."

    About ResMed: ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.  Contacts:
    For News Media For InvestorsGretchen Griswold

    Agnes LeeDirector, Global Corporate CommunicationsSenior Director, Investor RelationsO: 858-836-6789

    O: 858-836-5971news@resmed.com

    investorrelations@resmed.com


    '/>"/>
    SOURCE ResMed Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
    2. ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results
    3. ResMeds New Nasal Pillows System is Our Quietest Yet; Ultra-light AirFit P10 Packs Powerful Performance in Just over 1.5 Ounces
    4. ResMed Announces Conference Call And Webcast To Discuss Second Quarter 2014 Results
    5. BMC to protect its rights in patent fight with ResMed
    6. Apex reagiert energisch auf ResMed Patentklage
    7. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
    8. ResMed Inc. Announces Record Financial Results For The Quarter Ended September 30, 2013
    9. ResMeds New Nasal Mask Sets the Bar for Comfort and Performance
    10. ResMed Patent Infringement Case Against BMC Advances: International Trade Commission Agrees to Investigate
    11. Apex Fights Back Against ResMeds Patent Litigation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
    (Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
    (Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
    Breaking Medicine Technology:
    (Date:1/20/2017)... ... 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a unique ... Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of ... interacting with countless women who had little knowledge of the female characters portrayed in ...
    (Date:1/20/2017)... ... January 20, 2017 , ... ... Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior ... MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During ...
    (Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... of world hunger, and shares the simple and achievable answer. “The Land of More ... of the Fairview Missionary Church in Angola, Indiana where he works with the children’s ...
    (Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
    (Date:1/19/2017)... ... January 19, 2017 , ... ... and scientists from around the world, announces the launch of its newly redesigned ... easy portal to research breakthroughs and trending news, vital information on upcoming virtual ...
    Breaking Medicine News(10 mins):